Get started
Myriad Genetics, Inc.Myriad Genetics, Inc.Myriad Genetics, Inc.

Myriad Genetics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MYGN chart


Full chart

MYGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.22 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.30 USD
Net income (FY)
‪−263.30 M‬ USD
Revenue (FY)
‪753.20 M‬ USD
Shares float
‪87.62 M‬
Beta (1Y)
1.61

Employees


Employees (FY)
‪2.7 K‬
Change (1Y)
+100 +3.85%
Revenue / Employee (1Y)
‪278.96 K‬ USD
Net income / Employee (1Y)
‪−97.52 K‬ USD

About Myriad Genetics, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Paul J. Diaz
Website
myriad.com
Headquarters
Salt Lake City
Founded
1991
FIGI
BBG000D9H9F1
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MYGN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MYGN is 13.36 USD — it has increased by 1.44% in the past 24 hours. Watch Myriad Genetics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Myriad Genetics, Inc. stocks are traded under the ticker MYGN.
MYGN stock has fallen by −6.83% compared to the previous week, the month change is a −10.52% fall, over the last year Myriad Genetics, Inc. has showed a −32.25% decrease.
We've gathered analysts' opinions on Myriad Genetics, Inc. future price: according to them, MYGN price has a max estimate of 35.00 USD and a min estimate of 8.00 USD. Watch MYGN chart and read a more detailed Myriad Genetics, Inc. stock forecast: see what analysts think of Myriad Genetics, Inc. and suggest that you do with its stocks.
MYGN reached its all-time high on Nov 6, 2000 with the price of 65.80 USD, and its all-time low was 1.37 USD and was reached on Aug 31, 1998. View more price dynamics on MYGN chart.
See other stocks reaching their highest and lowest prices.
MYGN stock is 3.99% volatile and has beta coefficient of 1.61. Track Myriad Genetics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Myriad Genetics, Inc. there?
Today Myriad Genetics, Inc. has the market capitalization of ‪1.22 B‬, it has decreased by −4.76% over the last week.
Yes, you can track Myriad Genetics, Inc. financials in yearly and quarterly reports right on TradingView.
Myriad Genetics, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MYGN earnings for the last quarter are 0.06 USD per share, whereas the estimation was 0.02 USD resulting in a 220.15% surprise. The estimated earnings for the next quarter are 0.03 USD per share. See more details about Myriad Genetics, Inc. earnings.
Myriad Genetics, Inc. revenue for the last quarter amounts to ‪213.30 M‬ USD, despite the estimated figure of ‪210.76 M‬ USD. In the next quarter, revenue is expected to reach ‪213.31 M‬ USD.
MYGN net income for the last quarter is ‪−22.10 M‬ USD, while the quarter before that showed ‪−36.70 M‬ USD of net income which accounts for 39.78% change. Track more Myriad Genetics, Inc. financial stats to get the full picture.
No, MYGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has ‪2.70 K‬ employees. See our rating of the largest employees — is Myriad Genetics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Myriad Genetics, Inc. EBITDA is ‪−41.90 M‬ USD, and current EBITDA margin is −9.48%. See more stats in Myriad Genetics, Inc. financial statements.
Like other stocks, MYGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Myriad Genetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Myriad Genetics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Myriad Genetics, Inc. stock shows the strong sell signal. See more of Myriad Genetics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.